www.modernhealthcare.com

www.modernhealthcare.com
Share

www.modernhealthcare.com

 •  January 20

Four not-for-profit health systems last week announced they were taking on big pharma by creating their own generic-drug company. But experts caution it'll take years of navigating red tape and substantial investment before the operation stands a chance at lowering drug prices and alleviating shortages—if it does at all. In fact, previous attempts...

www.modernhealthcare.com

 •  January 18

Generic drugmakers faced a tumultuous trading day on the stock market Thursday following the news that four large health systems plan to enter their line of business. Intermountain Healthcare, Ascension, SSM Health and Trinity Health announced Thursday its aggressive plan to try to rein in the cost of drugs. Pharmaceutical company stocks were down...

www.modernhealthcare.com

 •  January 18

As four not-for-profit health systems unveiled plans to create their own generic drug company Thursday, experts say they'll face an uphill battle to make a significant dent in one of the fastest-growing industry expenses and persistent problems: rising drug prices and drug shortages. Intermountain Healthcare, Ascension, SSM Health and Trinity...

www.modernhealthcare.com

 •  November 14, 2017

FRANKLIN, Tenn. — Bringing a new drug to the market and getting it into the hands of patients who need it takes about 10 to 12 years and costs a whopping $2.6 billion. Pharmaceutical companies and healthcare providers should work together to speed up the process and drive costs out of the system, experts from both industries say. "There's always...

www.modernhealthcare.com

 •  October 3, 2017

Not-for-profit and public hospitals are reining back their spending as they cope with rising drug prices and proposed cuts to the 340B program that continue to batter their margins. The gap between growth in not-for-profit and public providers' revenues and supply costs widened between 2015 and 2016, according to a report from Moody's Investors...

www.modernhealthcare.com

 •  September 23, 2017

MOUNTAIN VIEW, Ark.—Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year. Berry couldn't talk. Her face was drooping on one side. Her eyes couldn't focus. "She was basically unresponsive," Langston recalled. Berry, 78, was having a severe ischemic stroke. Each...

www.modernhealthcare.com

 •  September 16, 2017

The Food and Drug Administration this week is holding a public hearing on how risk assessments are conducted on new drugs. The agency is under immense pressure to reduce review and approval times of drugs in order to lower costs but also ensure medications are safe before they go to market. In 2014, the FDA implemented a more structured approach to...

www.modernhealthcare.com

 •  August 3, 2017

The Senate overwhelmingly passed bipartisan legislation Thursday that reauthorizes U.S. Food and Drug Administration's ability to collect user fees from drug and device makers. The FDA user-fee agreements, which are renegotiated every five years with the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, fund nearly...

www.modernhealthcare.com

 •  July 30, 2017

Health systems can expect drug prices to increase by 7.61% next year, largely due to the surging prices of branded, specialty medications, a group purchasing organization said Tuesday. Vizient said in its drug pricing forecast that it's seen a spike in purchases for products not offered on its contract, most of which are patented, branded...

www.modernhealthcare.com

 •  May 15, 2017

More consolidation among healthcare distributors and pharmacy benefit managers has led to higher drug prices, according to a new article. The major players in both the distribution market and the PBM sector dominate their markets, the article published Monday in the Journal of the American Medical Association said. As the firms grew, prices for...